RE: Slide15 (3)15 Dec 2023 13:30
Ophidian the real question everyone wants answering is WHEN it will be approved. On Wednesday the team had a huge opportunity shed some light on the avactas future going forward, they blew it.
The tech works and impressively by all accounts but they left so many gaps that could have been filled.
The fortnightly cohort was supposed to run with 7 , obviously not. Has 7 finished , should we just keep guessing and hoping the fortnightly starts shortly in 24 , these patients aren't going to be end of life so a realistic timeline can be given.
Still here but extremely frustrated